Replies to post #479386 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Exactly Senti. Thanks for taking time to spell it out. Give yourself a sticky. This is excellent DD.

[newman2021]

senti, interesting also to note is that Dr. Reardon is the PI of the Inovia's Phase1/2 CI combo results they are presenting at ASCO this time. Dr. Reardon still likes our DcVaxL as he understands when we combine DcVaxL with CI and TLR agonists, the combo destroys unmethylated hard to treat cancers too. Aren't we the emperors in the cancer world!! REGN is a partner in INO's trial; they have an TLR agonist too and they have Kevin Duffy now; What REGN doesn't have is DcVaxL. Well, going to be an epic war to snatch DcVaxL from MRK, imo. Is MRK going to announce something on June 7th premarket? Better I tell them.

https://finance.yahoo.com/news/inovio-announces-survival-results-ino-120000971.html

[Chiugray]

Definitely over my head, but biomarkers and each patient being their own control is definitely intriguing.

(In one breath) It would make sense, if I'm understanding correctly, that if there is a meta database that can calibrate the median survival of GBM patients by their biomarkers, with some confidence level, such that it qualifies as a control group, then each DCVax-L trial patient, based on their biomarkers, their actual survival months can then be measured for efficacy against this control group, i.e. each patient as a control. All this is supplementary information of course because there is not an official endpoint in the trial for this.

[biosectinvestor]

One of the unique aspects of the crossover trials. I had read about it early on in my research but it did not seem to be relevant here. I'm so glad they may be able to make this kind of analysis. It will only bolster other evidence. Poor Adam.